EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The use of direct oral anticoagulants in the secondary prevention of venous thromboembolism in patients with severe thrombophilia: communication from the ISTH SSC Subcommittee on Physiological Anticoagulants and Thrombophilia

Mirjana Kovac, Vera Ignjatovic, Christelle Orlando, Zsuzsanna Bereczky, Beverley J Hunt

Journal of Thrombosis and Haemostasis · 2024-11 · 22 (11) · 3322-3329

DOI: 10.1016/j.jtha.2024.08.006 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024-11. Verfasst von Mirjana Kovac und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Belgrade, Belgrade, Serbia; Hemostasis Department, Blood Transfusion Institute of Serbia, Belgrade, Serbia. Electr…. Hauptthemen laut MEDLINE: Anticoagulants, Hemorrhage, Secondary Prevention, Thrombophilia. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Direct oral anticoagulants (DOACs) are the first-line anticoagulants for the secondary prevention of venous thromboembolism (VTE). However, patients with severe inherited thrombophilias represent a group in whom the efficiency and safety of DOACs is poorly studied. In this communication, we focus on the utility of DOACs in the secondary prevention of VTE in patients with severe thrombophilia. Current evidence is based only on cohort or single-center studies, and poor data are available on compliance of the patients in the studies. Analysis of the studies suggested that full-dose DOACs and vitamin K antagonists have a similar efficacy and bleeding risk in the secondary prevention of VTE in patients with thrombophilia, with a low hazard ratio for recurrent VTE calculated from cohort studies for DOAC vs warfarin, ranging from 0.3 to 0.75. We wish to highlight that treatment failure is greater in those with severe forms of protein S deficiency (below 20%) and possibly in antithrombin deficiency type II heparin-binding site homozygous Budapest 3. In summary, the current approach to using DOACs in patients with severe thrombophilia is dependent on clinical judgment and experience. Limited evidence suggests that for those with severe thrombophilias, full-dose DOACs have similar utility as vitamin K antagonists. We recommend caution in using low-dose DOACs due to lack of evidence. Ideally, large randomized multicenter studies are required to develop a reliable treatment algorithm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsHemorrhageSecondary PreventionThrombophiliaVenous ThromboembolismHumansAdministration, OralBlood CoagulationFactor Xa InhibitorsRecurrenceRisk AssessmentRisk FactorsSeverity of Illness IndexTreatment OutcomeVitamin K

Stichwörter der Autor:innen

antithrombin deficiencyprotein C deficiencyprotein S deficiencysecondary prevention of venous thromboembolism

Substanzen

AnticoagulantsFactor Xa InhibitorsVitamin K

Autor:innen und Institutionen

  • Faculty of Medicine, University of Belgrade, Belgrade, Serbia; Hemostasis Department, Blood Transfusion Institute of Serbia, Belgrade, Serbia. Electronic address: mkovac008@gmail.com.
  • Johns Hopkins All Children's Institute for Clinical & Translational Research, St. Petersburg, Florida, USA; Johns Hopkins University School of Medicine, St. Petersburg, Florida, USA.
  • Department of Hematology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
  • Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Haemostasis & Thrombosis Centre, Guy's and St Thomas' Hospital NHS Foundation Trust, Westminster Bridge Road, London, United Kingdom.

Zitieren

APA

Kovac, M., Ignjatovic, V., Orlando, C., Bereczky, Z., & Hunt, B. J. (2024). The use of direct oral anticoagulants in the secondary prevention of venous thromboembolism in patients with severe thrombophilia: communication from the ISTH SSC Subcommittee on Physiological Anticoagulants and Thrombophilia. Journal of Thrombosis and Haemostasis, 22(11), 3322-3329. https://doi.org/10.1016/j.jtha.2024.08.006

Vancouver

Kovac M, Ignjatovic V, Orlando C, Bereczky Z, Hunt BJ. The use of direct oral anticoagulants in the secondary prevention of venous thromboembolism in patients with severe thrombophilia: communication from the ISTH SSC Subcommittee on Physiological Anticoagulants and Thrombophilia. Journal of Thrombosis and Haemostasis. 2024;22(11):3322-3329. doi:10.1016/j.jtha.2024.08.006

BibTeX
@article{Kovac2024,
  author = {Kovac, Mirjana and Ignjatovic, Vera and Orlando, Christelle and Bereczky, Zsuzsanna and Hunt, Beverley J},
  title = {The use of direct oral anticoagulants in the secondary prevention of venous thromboembolism in patients with severe thrombophilia: communication from the ISTH SSC Subcommittee on Physiological Anticoagulants and Thrombophilia},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2024},
  volume = {22},
  number = {11},
  pages = {3322--3329},
  doi = {10.1016/j.jtha.2024.08.006}
}
Kostenlos starten →